Dongxing Medical: Intends to pay cash to purchase 90% of the equity of Wuhan Yijia Bao Biotechnology Co., Ltd.

East Star Medical announcement: it is planned to acquire 90% of the equity of Wuhan Yijiabao Biomedical Materials Co., Ltd. in cash. If the transaction can be successfully implemented, Wuhan Yijiabao will become a subsidiary of the company. This transaction is expected to constitute a significant asset restructuring as stipulated by the "Regulations on the Management of Major Asset Restructuring of Listed Companies". This transaction does not involve the issuance of shares by the listed company, does not constitute a related party transaction, and will not result in changes to the controlling shareholder or actual controller of the listed company.